Charles Evan Ballantyne's Net Worth
$97.9 Thousand
Who is Charles Evan Ballantyne?
Charles Evan Ballantyne does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include AGENUS INC, Synthetic Biologics, Inc., Gain Therapeutics, Inc., and CLINICAL DATA INC.
SEC CIK
Charles Evan Ballantyne's CIK is 0001371742
Past Insider Trading and Trends
2007 was Charles Evan Ballantyne's most active year for acquiring shares with 15 total transactions. Charles Evan Ballantyne's most active month to acquire stocks was the month of November. 2011 was Charles Evan Ballantyne's most active year for disposing of shares, totalling 7 transactions. Charles Evan Ballantyne's most active month to dispose stocks was the month of March. 2015 saw Charles Evan Ballantyne paying a total of $1,517,500.00 for 360,000 shares, this is the most they've acquired in one year. In 2011 Charles Evan Ballantyne cashed out on 390,600 shares for a total of $6,368,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AGENUS INC (AGEN) Snapshot price: $4.95
CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4/A
| +147.95% | 14.79K |
$4.15 | $61,399.25 | 24.8K |
Apr 26
| |||
Form 4
|
∞
| 14.65K |
$4.15 | $60,789.20 | 14.65K |
Apr 26
| |||
Form 4
|
∞
| 10K |
$5.05 | $50,500.00 | 10K |
Sep 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Synthetic Biologics, Inc. (TOVX) Snapshot price: $4.37
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 8
| |||
Form 4
|
∞
| 10K |
$1.35 | $13,500.00 | 10K |
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Gain Therapeutics, Inc. (GANX) Snapshot price: $1
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CLINICAL DATA INC No price found
EVP, CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -5.60K |
$30.00 | -$168,000.00 |
0
|
Apr 12 - Apr 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 17
| |||
Form 4
| +3.70% | 200 |
$22.00 | $4,400.00 | 5.6K |
Dec 14
| |||
Form 4
| +44.00% | 1.65K |
$21.51 | $35,489.40 | 5.4K |
Dec 14
| |||
Form 4
| +150.00% | 1.5K |
$26.60 | $39,896.00 | 2.5K |
Sep 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
| +150.00% | 600 |
$16.79 | $10,074.00 | 1K |
Dec 11
| |||
Form 4/A
|
∞
| 400 |
$12.46 | $4,984.00 | 400 |
Aug 21
| |||
Form 4
|
∞
| 400 |
$12.46 | $4,984.00 | 400 |
Aug 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||